Terms: = Leukemia AND Neurokinin
24 results:
1. Aprepitant Sensitizes Acute Myeloid leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo.
Wu H; Cheng X; Huang F; Shao G; Meng Y; Wang L; Wang T; Jia X; Yang T; Wang X; Fu C
Drug Des Devel Ther; 2020; 14():2413-2422. PubMed ID: 32606608
[TBL] [Abstract] [Full Text] [Related]
2. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Gavriatopoulou M; Chari A; Chen C; Bahlis N; Vogl DT; Jakubowiak A; Dingli D; Cornell RF; Hofmeister CC; Siegel D; Berdeja JG; Reece D; White D; Lentzsch S; Gasparetto C; Huff CA; Jagannath S; Baz R; Nooka AK; Richter J; Abonour R; Parker TL; Yee AJ; Moreau P; Lonial S; Tuchman S; Weisel KC; Mohty M; Choquet S; Unger TJ; Li K; Chai Y; Li L; Shah J; Shacham S; Kauffman MG; Dimopoulos MA
Leukemia; 2020 Sep; 34(9):2430-2440. PubMed ID: 32094461
[TBL] [Abstract] [Full Text] [Related]
3. Hemokinin-1 stimulates C-C motif chemokine ligand 24 production in macrophages to enhance eosinophilic inflammation in nasal polyps.
Deng YK; Ma J; Wang ZC; Long XB; Chen CL; Feng QM; Zhang XH; Zeng M; Wang H; Lu X; Liu Z
Int Forum Allergy Rhinol; 2019 Nov; 9(11):1334-1345. PubMed ID: 31545881
[TBL] [Abstract] [Full Text] [Related]
4. neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload.
Ge C; Huang H; Huang F; Yang T; Zhang T; Wu H; Zhou H; Chen Q; Shi Y; Sun Y; Liu L; Wang X; Pearson RB; Cao Y; Kang J; Fu C
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19635-19645. PubMed ID: 31488714
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract] [Full Text] [Related]
6. A phase II open-label study of aprepitant as anti-emetic prophylaxis in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy.
Brandwein JM; Seki JT; Atenafu EG; Rostom A; Lutynski A; Rydlewski A; Schimmer AD; Schuh AC; Gupta V; Yee KWL
Support Care Cancer; 2019 Jun; 27(6):2295-2300. PubMed ID: 30341536
[TBL] [Abstract] [Full Text] [Related]
7. neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis: Shedding new light on resistance to Aprepitant.
Bashash D; Safaroghli-Azar A; Bayati S; Razani E; Pourbagheri-Sigaroodi A; Gharehbaghian A; Momeny M; Sanjadi M; Rezaie-Tavirani M; Ghaffari SH
Int J Biochem Cell Biol; 2018 Oct; 103():105-114. PubMed ID: 30145367
[TBL] [Abstract] [Full Text] [Related]
8. Human acute myeloid leukemia cells express neurokinin-1 receptor, which is involved in the antileukemic effect of neurokinin-1 receptor antagonists.
Molinos-Quintana A; Trujillo-Hacha P; Piruat JI; Bejarano-García JA; García-Guerrero E; Pérez-Simón JA; Muñoz M
Invest New Drugs; 2019 Feb; 37(1):17-26. PubMed ID: 29721755
[TBL] [Abstract] [Full Text] [Related]
9. Antileukemic effects of neurokinin-1 receptor inhibition on hematologic malignant cells: a novel therapeutic potential for aprepitant.
Bayati S; Razani E; Bashash D; Safaroghli-Azar A; Safa M; Ghaffari SH
Anticancer Drugs; 2018 Mar; 29(3):243-252. PubMed ID: 29389803
[TBL] [Abstract] [Full Text] [Related]
10. [Gastroesophageal reflux disease in patients receiving chemotherapy: clinical, endoscopic, morphological and immunohistochemical features].
Gricenko TA; Davydkin IL; Osadchuk AM; Kostalanova JV
Eksp Klin Gastroenterol; 2015; (2):17-23. PubMed ID: 25993868
[TBL] [Abstract] [Full Text] [Related]
11. Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine.
Badar T; Cortes J; Borthakur G; O'Brien S; Wierda W; Garcia-Manero G; Ferrajoli A; Kadia T; Poku R; Kantarjian H; Mattiuzzi G
Biomed Res Int; 2015; 2015():497597. PubMed ID: 25654108
[TBL] [Abstract] [Full Text] [Related]
12. [Efficacy of granisetron for preventing chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia treated with a combination of anthracycline and cytarabine].
Goto T; Tanimoto K; Ishibashi M; Okamura S
Gan To Kagaku Ryoho; 2012 Aug; 39(8):1227-32. PubMed ID: 22902447
[TBL] [Abstract] [Full Text] [Related]
13. Expression and proliferative effect of hemokinin-1 in human B-cells.
Grassin-Delyle S; Buenestado A; Vallat L; Naline E; Marx S; Decocq J; Debré P; Bernard OA; Advenier C; Devillier P; Merle-Béral H
Peptides; 2011 May; 32(5):1027-34. PubMed ID: 21334411
[TBL] [Abstract] [Full Text] [Related]
14. The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.
Muñoz M; González-Ortega A; Coveñas R
Invest New Drugs; 2012 Apr; 30(2):529-40. PubMed ID: 21120581
[TBL] [Abstract] [Full Text] [Related]
15. [Substance P as a regulatory peptide of hematopoiesis and blood cell functions].
Adamus M
Postepy Hig Med Dosw (Online); 2009 Mar; 63():106-13. PubMed ID: 19252469
[TBL] [Abstract] [Full Text] [Related]
16. neurokinin-A inhibits cell cycle activators in K562 cells and activates Smad 4 through a non-canonical pathway: a novel method in neural-hematopoietic axis.
Ricardo M; Trzaska KA; Rameshwar P
J Neuroimmunol; 2008 Nov; 204(1-2):85-91. PubMed ID: 18760489
[TBL] [Abstract] [Full Text] [Related]
17. Implication of possible therapies targeted for the tachykinergic system with the biology of neurokinin receptors and emerging related proteins.
Rameshwar P
Recent Pat CNS Drug Discov; 2007 Jan; 2(1):79-84. PubMed ID: 18221219
[TBL] [Abstract] [Full Text] [Related]
18. LIF upregulates expression of NK-1R in NHBE cells.
Hu CP; Feng JT; Tang YL; Zhu JQ; Lin MJ; Yu ME
Mediators Inflamm; 2006; 2006(5):84829. PubMed ID: 17392578
[TBL] [Abstract] [Full Text] [Related]
19. Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.
Lai JP; Ho WZ; Zhan GX; Yi Y; Collman RG; Douglas SD
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3970-5. PubMed ID: 11274418
[TBL] [Abstract] [Full Text] [Related]
20. [Membrane metalloendopeptidase (CD10/CALLA): distribution, physiologic and pathophysiologic functions and its inhibitors].
Stanović S; Boranić M
Lijec Vjesn; 1998 May; 120(5):131-7. PubMed ID: 9748792
[TBL] [Abstract] [Full Text] [Related]
[Next]
